Concepedia

Publication | Closed Access

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

111

Citations

0

References

2005

Year

Ulrike Möbius, Margrit Lubach-Ruitman, Brigitte Castro-Frenzel, Matthias Stoll, Esther Voigt, Stefan Christensen, Jörg‐Andres Rump, Gerd Fätkenheuer, Georg M. N. Behrens, Reinhold E. Schmidt
PubMed

Abstract

Switching to atazanavir results in a significant improvement in HIV therapy-induced hyperlipidemia. A switch to atazanavir is proposed as a valuable option to improve atherogenic lipid profiles while maintaining virologic control.